Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer.

Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers.

Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit genuine and differential physical and biological properties compared to benign prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in PCa.

Oncotarget. 2016 Jan 12 [Epub ahead of print]

Felix Royo, Patricia Zuñiga-Garcia, Verónica Torrano, Ana Loizaga, Pilar Sanchez-Mosquera, Aitziber Ugalde-Olano, Esperanza González, Ana R Cortazar, Laura Palomo, Sonia Fernández-Ruiz, Isabel Lacasa-Viscasillas, Maria Berdasco, James D Sutherland, Rosa Barrio, Amaia Zabala-Letona, Natalia Martín-Martín, Amaia Arruabarrena-Aristorena, Lorea Valcarcel-Jimenez, Alfredo Caro-Maldonado, Jorge Gonzalez-Tampan, Guido Cachi-Fuentes, Manel Esteller, Ana M Aransay, Miguel Unda, Juan M Falcón-Pérez, Arkaitz Carracedo

PubMed

CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , Department of Urology, Basurto University Hospital, Bilbao, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , Department of Pathology, Basurto University Hospital, Bilbao, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , Department of Urology, Basurto University Hospital, Bilbao, Spain. , Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , Department of Urology, Basurto University Hospital, Bilbao, Spain. , Department of Urology, Basurto University Hospital, Bilbao, Spain. , Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , Department of Urology, Basurto University Hospital, Bilbao, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain. , CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe